Content deleted Content added
Updating {{drugbox}} (changes to verified and watched fields - added verified revid - updated 'DrugBank_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wikipedia talk:WikiProject_Pharmac |
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot |
||
Line 1: | Line 1: | ||
{{unreferenced|date=November 2006}} |
{{unreferenced|date=November 2006}} |
||
{{ |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
| Watchedfields = changed |
||
Line 6: | Line 6: | ||
| IUPAC_name = 2-diethylaminoethyl 4-amino-3-butoxy-benzoate |
| IUPAC_name = 2-diethylaminoethyl 4-amino-3-butoxy-benzoate |
||
| image = Oxybuprocaine.svg |
| image = Oxybuprocaine.svg |
||
<!--Clinical data--> |
|||
| tradename = |
|||
| Drugs.com = {{drugs.com|international|oxybuprocaine}} |
|||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Pharmacokinetic data--> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Identifiers--> |
|||
| CASNo_Ref = {{cascite|correct|CAS}} |
| CASNo_Ref = {{cascite|correct|CAS}} |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| ChemSpiderID = 4472 |
| ChemSpiderID = 4472 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = AXQ0JYM303 |
| UNII = AXQ0JYM303 |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
||
| ChEMBL = 1200 |
| ChEMBL = 1200 |
||
<!--Chemical data--> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3 |
| StdInChI = 1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3 |
||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChIKey = CMHHMUWAYWTMGS-UHFFFAOYSA-N |
| StdInChIKey = CMHHMUWAYWTMGS-UHFFFAOYSA-N |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
}} |
}} |
||
'''Oxybuprocaine''' ([[International Nonproprietary Name|INN]]), also known as '''benoxinate''' or '''BNX''', is the name of a [[local anesthetic]], which is used especially in [[ophthalmology]] and [[otolaryngology]]. Oxybuprocaine is sold by [[Novartis]] under the brand names '''Novesine''' or '''Novesin'''. |
'''Oxybuprocaine''' ([[International Nonproprietary Name|INN]]), also known as '''benoxinate''' or '''BNX''', is the name of a [[local anesthetic]], which is used especially in [[ophthalmology]] and [[otolaryngology]]. Oxybuprocaine is sold by [[Novartis]] under the brand names '''Novesine''' or '''Novesin'''. |
Revision as of 07:55, 30 August 2011
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H29ClN2O3 |
Molar mass | 344.877 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Oxybuprocaine (INN), also known as benoxinate or BNX, is the name of a local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine is sold by Novartis under the brand names Novesine or Novesin.
Safety for use in pregnancy and lactation has not been established.
Surgical use
- In ophthalmology in order to numb the surface of the eye (the outermost layers of the cornea and conjunctiva) for the following purposes:
- In order to perform a contact/applanation tonometry.
- In order to remove small foreign objects from the uppermost layer of the cornea or conjunctiva.
- In otolaryngology for numbing the mucous membranes of the nostrils.
Adverse effects
Oxybuprocaine like any other topical anesthetic used in the eye (like for example tetracaine, proxymetacaine and proparacaine) can cause irreversible corneal damage and even complete destruction of the cornea when used excessively (excessive use means several times a day during several days or even weeks).